An interventional study of S.M.A.R.T. RADIANZ™ Vascular Stent System and BRITE TIP RADIANZ™ Guiding Sheath in Peripheral Arterial Disease, sponsored by Cordis US Corp.. Completed at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Cordis US Corp. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Peripheral Arterial Disease with a site in Austria — 7 open to participants now, 16 under way, 2 of them phase 3. Peripheral Arterial Disease · Austria.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, this one is the 30th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2022, is one of 41 with no phase, and was the 62nd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 74 studies in Peripheral Arterial Disease with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Graz · Sites in Austria
Ages 18+
Biotronik AG · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
CSL Behring · Sites in Austria, United States, Argentina and 32 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria
Ages 18–99 · Healthy volunteers
Medical University Innsbruck · Sites in Austria
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 11 · Phase 4 4
First in 2004; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 170 across the 58 interventional studies, 376 across the 16 observational. Of the 49 that completed or were terminated, 20 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 74 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cordis US Corp., one of the names counted as Cordis Corporation. Under that name alone:
Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Cordis Corporation has 6 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT04912323R3 Vascular Inc.Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease | 2026-12-31 |
| NCT07465627Medical University of GrazVessel Recoil in Specific CLTI Populations | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this clinical investigation was to evaluate acute safety and efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System, when used with the BRITE TIP RADIANZ™ Guiding Sheath and SABERX RADIANZ™ PTA Balloon Catheter, to deploy the S.M.A.R.T.™ Nitinol Stent, in the treatment of patients with obstructive iliac or femoropopliteal arterial disease via radial artery access.
RADIANCY was an acute, multi-center, single-arm, non-randomized, prospective, pivotal (pre-market) clinical study, whose primary objective was to evaluate acute safety and efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System, when used with the BRITE TIP RADIANZ™ Guiding Sheath and SABERX RADIANZ™ PTA Balloon Catheter, to deploy the S.M.A.R.T.™ self-expanding stent in the treatment of patients with obstructive iliac or femoropopliteal arterial disease via transradial artery access. The study enrolled 151 subjects, 22 of which were enrolled as "roll-in" subjects, at 12 investigational sites across Europe. These subjects were followed up to 30 days post-procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet ALL of the following inclusion criteria to be enrolled in the study:
ALL patients must meet the following criteria prior to enrollment:
Per Investigator assessment, the patient is willing and able to be followed up to 30 days post-procedure for evaluation and complete all required assessments per the study protocol.
Inclusion criteria 9 and 10 AND 11a through 14a OR 11b through 16b (whichever is applicable) would be assessed via baseline angiography performed at the time of index procedure:
Patients whose target lesion is in the iliac artery must meet these additional criteria prior to enrollment:
11a. A single de novo or restenotic lesion ≥ 50% stenosis in the common and/or external iliac artery
12a. Stenotic lesion (one long or multiple serial/tandem lesions) less than or equal to 100 mm, by visual assessment, within or across the common or external iliac arteries. The stenosis must be treatable with no more than two stents (while minimizing stent overlap)
13a. Reference vessel diameter (RVD) ranging from 4.0 to 9.0 mm by visual assessment
14a. Angiographic evidence of a patent profunda or superficial femoral artery in the diseased (target) limb
Patients whose target lesion is in the SFA and/or PPA must meet these additional criteria prior to enrollment:
11b. A single de novo or restenotic lesion ≥ 50% stenosis in the SFA and/or PPA
12b. Stenotic lesion (one long or multiple serial/tandem lesions) less than or equal to 150 mm, by visual assessment, within or across the SFA and/or PPA. The stenosis must be treatable with no more than two stents (while minimizing stent overlap)
13b. RVD ranging from 4.0 to 7.0 mm by visual assessment
14b. All lesions are to be located at least three centimeters proximal to the superior edge of the patella
15b. Patent infrapopliteal artery, i.e., single vessel runoff or better with patency (\<50% stenosis) of at least one of three vessels to the ankle or foot
16b. Adequate aortoiliac or common femoral "inflow" (defined as \< 30% stenosis after PTA or stenting) prior to treatment of the target lesion (defined as \< 30% stenosis after PTA or stenting) prior to treatment of the target lesion
Exclusion Criteria:
Patients will be excluded if ANY of the following exclusion criteria apply:
Patient has had a major surgical or interventional procedure unrelated to this study within 30 days prior to enrollment or is anticipated/planned to have such a procedure within 30 days after enrollment.
Exclusion criteria 20 through 25 would be assessed via baseline angiography performed at the time of index procedure:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with SMART RADIANZ, BRITE TIP RADIANZ and SABERX RADIANZ devices
Device: S.M.A.R.T. RADIANZ™ Vascular Stent System · Device: BRITE TIP RADIANZ™ Guiding Sheath · Device: SABERX RADIANZ™ PTA Balloon Catheter
The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome)
Occurrence rate of CEC-adjudicated, major radial access site complications attributed to study device or procedure through time of hospital discharge.
Time frame: From the time of sheath introduction through the radial artery (start time of procedure) through time of discharge (within ~48 hours of end time of procedure) or study exit, whichever comes first
Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome)
Technical success at the conclusion of the index procedure, defined as successful insertion of the S.M.A.R.T. RADIANZ™ Vascular Stent System into the peripheral vasculature through the radial artery, successful deployment of the study device (S.M.A.R.T.™ stent) at the intended location, and successful withdrawal of the delivery system without conversion from radial to femoral artery access.
Time frame: From the time of insertion to the time of withdrawal of the SMART RADIANZ Vascular Stent System through the radial access artery, within the same day or 24 hours from the procedure start time
Device Deficiencies Through 30 Days Post-Procedure
For each of the three (3) devices, peri-procedural (within 30 days post-index procedure) rate of device deficiencies
Time frame: From the time of first use/handling of the device to 30 days from date of index procedure or study exit, whichever comes first
Adverse Events Through 30 Days Post-Procedure
Peri-procedural (within 30 days post-index procedure) rate of adverse events
Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Death, Index Limb Amputation and TLR Through 30 Days Post-Procedure
Peri-procedural (within 30 days post-index procedure) rate of death, index limb amputation and target lesion revascularization
Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Procedural Complications Through 30 Days Post-Procedure
Peri-procedural (within 30 days post-index procedure) rate of procedural complications
Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Technical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath
Technical success associated with use of the BRITE TIP RADIANZ™ Guiding Sheath, defined as successful insertion of the device into the peripheral vasculature through the radial artery (allowing for introduction of interventional and/or diagnostic devices) and successful withdrawal of the device.
Time frame: From the time of insertion through the time of withdrawal of the BRITE TIP RADIANZ™ Guiding Sheath through the radial access artery, assessed within the same day or 24 hours from the start time of the index procedure.
Procedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter
Procedural success associated with use of the SABERX RADIANZ™ PTA Balloon Catheter for pre-dilation and/or post-deployment stent dilatation (whenever applicable), defined as successful insertion of the device into the peripheral vasculature through the radial artery, successful inflation and deflation of the balloon, successful withdrawal of the device, and achievement of a final residual diameter stenosis of \< 30% at the conclusion of the index procedure.
Time frame: From the time of insertion to the time of withdrawal of the SABERX RADIANZ™ PTA Balloon Catheter through the radial access artery AND assessment of the final residual diameter stenosis, within the same day or 24 hours from the procedure start time
Fluoroscopy Time
Fluoroscopy time is the length of time during which X-rays are produced during a fluoroscopy procedure.
Time frame: From the start time to the end time of the period during which x-rays are produced, within the same day or 24 hours from the procedure start time
Time to Achieve Hemostasis
Time to achieve hemostasis defined as the time elapsed from removal of the BRITE TIP RADIANZTM Guiding Sheath to the time that hemostasis was first observed.
Time frame: From the time of removal of the BRITE TIP RADIANZ Guiding Sheath to when hemostasis was first observed, within the same day or 24 hours from the procedure start time
Time to Ambulation
Time to ambulation, defined as the time from when vascular closure was achieved to when the subject could stand up and walk any distance
Time frame: From the time of vascular closure to the time of ambulation, within the same day or 24 hours from the procedure start time, or study exit, whichever comes first
Time to Hospital Discharge
Time to hospital discharge
Time frame: From the time of vascular closure to the time of hospital discharge (~ up to 1 week from date of index procedure) or study exit, whichever comes first
Method to Achieve Closure of the Transradial Artery Access Site
Method to achieve closure of the transradial artery access site
Time frame: From the time of removing the BRITE TIP RADIANZ Guiding Sheath to the time of either removing the vascular closure device or ending manual compression, within the same day or 24 hours from the procedure start time
Quality of Life Assessed Via the SF-36 Questionnaires - General Health
Mean scores are reported on a scale entitled "mean score" and range from 0 (minimum) to 100 (maximum); higher scores represent a better outcome.
Time frame: Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)
Quality of Life Assessed Via the EuroQOL-5 Dimensions (EQ-5D) Questionnaire - Overall Health
The EQ-5D questionnaire is an instrument designed to assess quality of life along five (5) dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each participant, a value-based scoring system is used to convert the combination of their responses to the five individual subscales into a single index value (or a code), which is then converted into a single score based on how people in the participant's country rate different combinations of problems. The EQ-5D score for Overall Health is reported as a mean and standard deviation at screening, discharge and 30 days in this module and ranges from 0 (minimum) to 100 (maximum) with higher scores representing better outcomes.
Time frame: Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)
Time to Hospital Discharge Eligibility
Time to hospital discharge eligibility (when physician examines and if all is well, gives discharge orders)
Time frame: From the time of vascular closure to the time of hospital discharge eligibility (~ up to 1 week from date of index procedure) or study exit, whichever comes first
Procedural Time
Procedural Time is defined as the time elapsed from when the sheath was introduced through the radial access artery to the time of vascular closure.
Time frame: From the time of introduction of the sheath through the radial access artery to the time of vascular closure, within the same day or 24 hours from the procedure start time
A total of 151 enrolled subjects were enrolled between June 29, 2022 and September 22, 2023 at 12 institutions/hospitals across 6 European countries.
| Milestone | Main Cohort | Roll-in Cohort |
|---|---|---|
| Started | 129 | 22 |
| Completed | 128 | 21 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 0 | 1 |
Occurrence rate of CEC-adjudicated, major radial access site complications attributed to study device or procedure through time of hospital discharge.
| Participants | Interventional |
|---|---|
| Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome) | 0 |
Technical success at the conclusion of the index procedure, defined as successful insertion of the S.M.A.R.T. RADIANZ™ Vascular Stent System into the peripheral vasculature through the radial artery, successful deployment of the study device (S.M.A.R.T.™ stent) at the intended location, and successful withdrawal of the delivery system without conversion from radial to femoral artery access.
| Participants | Interventional |
|---|---|
| Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome) | 122 |
For each of the three (3) devices, peri-procedural (within 30 days post-index procedure) rate of device deficiencies
| Participants | Interventional |
|---|---|
| BRITE TIP RADIANZ | 1 |
| SMART RADIANZ | 1 |
| SABERX RADIANZ | 0 |
Peri-procedural (within 30 days post-index procedure) rate of adverse events
| Participants | Interventional |
|---|---|
| Adverse Events Through 30 Days Post-Procedure | 24 |
Peri-procedural (within 30 days post-index procedure) rate of death, index limb amputation and target lesion revascularization
| Participants | Interventional |
|---|---|
| Death | 0 |
| Index Limb Amputation | 1 |
| Target Lesion Revascularization | 0 |
Peri-procedural (within 30 days post-index procedure) rate of procedural complications
| Participants | Interventional |
|---|---|
| No Conversion from Radial Artery | 128 |
| BRITE TIP RADIANZ Insertion | 129 |
| Guidewire Across Target Lesion | 129 |
| SABERX RADIANZ Insertion | 128 |
| Balloon Inflation | 113 |
| S.M.A.R.T. RADIANZ Insertion | 123 |
| Stent Deployed | 117 |
Technical success associated with use of the BRITE TIP RADIANZ™ Guiding Sheath, defined as successful insertion of the device into the peripheral vasculature through the radial artery (allowing for introduction of interventional and/or diagnostic devices) and successful withdrawal of the device.
| Participants | Interventional |
|---|---|
| Technical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath | 129 |
Procedural success associated with use of the SABERX RADIANZ™ PTA Balloon Catheter for pre-dilation and/or post-deployment stent dilatation (whenever applicable), defined as successful insertion of the device into the peripheral vasculature through the radial artery, successful inflation and deflation of the balloon, successful withdrawal of the device, and achievement of a final residual diameter stenosis of \< 30% at the conclusion of the index procedure.
| Participants | Interventional |
|---|---|
| Procedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter | 79 |
Fluoroscopy time is the length of time during which X-rays are produced during a fluoroscopy procedure.
| minutes | Interventional |
|---|---|
| Fluoroscopy Time | 9 ± 4 |
Time to achieve hemostasis defined as the time elapsed from removal of the BRITE TIP RADIANZTM Guiding Sheath to the time that hemostasis was first observed.
| minutes | Interventional |
|---|---|
| Time to Achieve Hemostasis | 47 ± 20 |
Time to ambulation, defined as the time from when vascular closure was achieved to when the subject could stand up and walk any distance
| minutes | Interventional |
|---|---|
| Time to Ambulation | 207 ± 153 |
Time to hospital discharge
| hours | Interventional |
|---|---|
| Time to Hospital Discharge | 15.6 ± 9.5 |
Method to achieve closure of the transradial artery access site
| Participants | Interventional |
|---|---|
| Manual Compression | 2 |
| Radial Compression Band | 127 |
Mean scores are reported on a scale entitled "mean score" and range from 0 (minimum) to 100 (maximum); higher scores represent a better outcome.
| score on a scale | Interventional |
|---|---|
| Screening | 47.56 ± 17.67 |
| Discharge | 52.44 ± 15.10 |
| 30 Day Follow-Up | 60.71 ± 16.43 |
The EQ-5D questionnaire is an instrument designed to assess quality of life along five (5) dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each participant, a value-based scoring system is used to convert the combination of their responses to the five individual subscales into a single index value (or a code), which is then converted into a single score based on how people in the participant's country rate different combinations of problems. The EQ-5D score for Overall Health is reported as a mean and standard deviation at screening, discharge and 30 days in this module and ranges from 0 (minimum) to 100 (maximum) with higher scores representing better outcomes.
| score on a scale | Interventional |
|---|---|
| Screening | 63.20 ± 16.24 |
| Discharge | 70.66 ± 14.08 |
| 30 Day | 78.01 ± 13.95 |
Time to hospital discharge eligibility (when physician examines and if all is well, gives discharge orders)
| hours | Interventional |
|---|---|
| Time to Hospital Discharge Eligibility | 14.3 ± 10.1 |
Procedural Time is defined as the time elapsed from when the sheath was introduced through the radial access artery to the time of vascular closure.
| minutes | Interventional |
|---|---|
| Procedural Time | 47 ± 20 |
Collected over Peri-procedural (within 30 days post-index procedure). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Cohort | 0/129 (0%) | 5/129 (3.9%) | 10/129 (7.8%) |
| Roll-in Cohort | 1/22 (4.5%) | 6/22 (27.3%) | 0/22 (0%) |
| Event | Main Cohort | Roll-in Cohort |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/129 | 2/22 |
| Iliac artery perforationCardiac disorders | 0/129 | 1/22 |
| UlcerGeneral disorders | 0/129 | 1/22 |
| Wound complicationInjury, poisoning and procedural complications | 0/129 | 1/22 |
| Haemoglobin decreasedInvestigations | 0/129 | 1/22 |
| Rectal hemorrhageGastrointestinal disorders | 1/129 | 0/22 |
| Arterial injuryInjury, poisoning and procedural complications | 1/129 | 0/22 |
| Cerebrovascular accidentNervous system disorders | 1/129 | 0/22 |
| Skin necrosisSkin and subcutaneous tissue disorders | 1/129 | 0/22 |
| IschaemiaVascular disorders | 1/129 | 0/22 |
| Event | Main Cohort | Roll-in Cohort |
|---|---|---|
| Vascular access site haematomaGeneral disorders | 10/129 | 0/22 |
| Age, Continuous(Years) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Mean | 68.23 ± 9.44 | 68.45 ± 8.90 | 68.26 ± 9.44 |
| Sex: Female, Male(Participants) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Female | 34 | 3 | 37 |
| Male | 95 | 19 | 114 |
| Race and Ethnicity Not Collected(Participants) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Austria | 43 | 8 | 51 |
| Italy | 17 | 2 | 19 |
| France | 65 | 8 | 73 |
| Spain | 4 | 2 | 6 |
| Switzerland | 0 | 1 | 1 |
| Belgium | 0 | 1 | 1 |
| Medical History(Participants) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| COPD | 15 | 4 | 19 |
| Chronic Renal Failure | 4 | 4 | 8 |
| Diabetes Mellitus | 39 | 5 | 44 |
| Heart Failure | 6 | 1 | 7 |
| Hypercholesterolemia | 93 | 16 | 109 |
| Hypertension | 98 | 19 | 117 |
| Peripheral Artery Disease | 96 | 15 | 111 |
| Previous Cerebrovascular Accident | 7 | 1 | 8 |
| Previous Myocardial Infarction | 9 | 1 | 10 |
| Smoking | 91 | 18 | 109 |
| Smoking Unknown | 3 | 1 | 4 |
| Physical Examination Condition(Participants) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Peripheral Artery Disease Symptoms | 129 | 21 | 150 |
| Claudication Symptoms | 127 | 20 | 147 |
| Muscle Plain with Exercise | 110 | 17 | 127 |
| Critical Limb Symptoms | 12 | 3 | 15 |
| Pain at Rest | 13 | 1 | 14 |
| Height (cm)(centimeters) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Mean | 170.48 ± 8.30 | 172.5 ± 9.02 | 170.77 ± 8.41 |
| Weight (kg)(kg) | Main Cohort | Roll-in Cohort | Total |
|---|---|---|---|
| Mean | 77.01 ± 14.33 | 82.78 ± 15.42 | 77.85 ± 14.59 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Sep 2023, 14 months.
Results were first posted in Aug 2025, 1 year 10 months after primary completion.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 14 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.